{"Title":"Celcuity","Industry":"MEDICAL LABORATORIES","Employees":"15","Founded":"","Address":"","Phone":"(763) 392-0123","Web_address":"http://www.celcuity.com","Market_cup":"$92.4mil","Revenues":"$0 mil (last 12 months)","Net_income":"$-4.5 mil (last 12 months)","Symbol":"CELC","Exchange":"NASDAQ","Shares":"2.4","Price_range":"$9.50 - $9.50","Est_volume":"$22.8 mil","Manager":"Craig-Hallum Capital Group","CO_managers":"-","Exp_to_trade":"9/20/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. Our proprietary CELx diagnostic platform is the only commercially ready technology we are aware of that uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it."}